Daily News Podcast

Rivaroxaban beats aspirin for VTE


 

Both low-dose and full-dose rivaroxaban had superior benefit-risk profiles for extended VTE compared with aspirin. Also today, bone biopsy diagnostics for osteomyelitis vary widely, variation in bacterial drug susceptibility are tied to the risk of TB relapse, and CTA cuts MIs in patients with stable chest pain. Subscribe to the MDedge Daily News wherever you get your podcasts.
Amazon Alexa
Apple Podcasts
Spotify

Recommended Reading

An epidemic of non-alcoholic fatty liver disease
MDedge Neurology
AAN and others update practice guidelines for prolonged disorders of consciousness
MDedge Neurology
Sleepio app tied to reducing insomnia, depression
MDedge Neurology
5 digital HIPAA myths
MDedge Neurology
Screen for cervical cancer based on age, risk
MDedge Neurology
Is it time for PCPs to take over chronic HCV?
MDedge Neurology
Rivaroxaban data abound at ESC 2018
MDedge Neurology
New MI definition for infarction vs injury
MDedge Neurology
Lorcaserin shows cardiovascular safety
MDedge Neurology
Lung function decline linked to cardiovascular risk
MDedge Neurology